-
1.发明申请
公开(公告)号：WO2021100051A1
公开(公告)日：2021-05-27
申请号：PCT/IL2020/051209
申请日：2020-11-24
IPC分类号： A61K9/00 , A61K31/05 , A61K31/4035 , A61K31/07 , A61K31/327 , A61K31/573 , A61K31/7048 , A61P17/00 , A61P17/06 , A61P17/10 , A61P17/08
摘要： Provided herein is a topical combination composition comprising tapinarof, a PDE4 inhibitor and optionally at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO), a Janus kinase inhibitor (JAK inhibitor), a corticosteroid of potency class 1-4, an acaricide and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above compositions are useful for the treatment, prevention or alleviation of a skin disorder selected from psoriasis, dermatitis, acne, rosacea, ichthyosis, scaling skin, imbalance of skin barrier and tinea and exhibit synergistic and/or additive effects allowing to reduce the active agents amounts in the combination compositions.
-
2.发明申请
公开(公告)号：WO2021014453A1
公开(公告)日：2021-01-28
申请号：PCT/IL2020/050825
申请日：2020-07-23
发明人： ARKIN, Moshe , ZIGHELBOIM, Marcel , NOV, Ori , TOLEDANO, Ofer
IPC分类号： A61K31/519 , A61K31/05 , A61K31/07 , A61P31/04 , A61K31/573 , A61K31/7048 , A61P17/00 , A61P17/10
摘要： Provided herein is a topical combination composition and a method of treatment of an inflammatory skin condition by administration of said composition comprising at least one Janus kinase inhibitor (JAK inhibitor) and at least one additional active agent selected from benzoyl peroxide (BPO), at least one retinoid, tapinarof, at least one antibiotic, at least one antiandrogen, at least one acaricide and combinations thereof and a carrier suitable for topical administration. The JAK inhibitor and the at least one additional active agent exhibit an additive or synergistic effect, allowing to reduce the amounts of active agents in the composition.
-
3.发明申请
公开(公告)号：WO2021059283A1
公开(公告)日：2021-04-01
申请号：PCT/IL2020/051053
申请日：2020-09-24
发明人： ARKIN, Moshe , ZIGHELBOIM, Marcel
摘要： Provided herein is a topical composition comprising tapinarof and methods of treatment of cutaneous adverse effects caused by oncological therapy with the tapinarof composition. The tapinarof compositions of this invention are useful for the treatment, prevention or amelioration of cutaneous and/or mucosal adverse effect caused by oncological therapy selected from chemotherapy, immunotherapy, radiation therapy, targeted therapy, hormone therapy and stem cell transplant therapy.
-
公开(公告)号：WO2020212982A1
公开(公告)日：2020-10-22
申请号：PCT/IL2020/050441
申请日：2020-04-16
发明人： ARKIN, Moshe
IPC分类号： A61K31/05 , A61K31/635 , A61K31/58 , A61K31/606 , A61P1/00 , A61K9/00
摘要： Provided herein is a rectal composition for the treatment of GI disorders, comprising a therapeutically effective amount of tapinarof and a carrier suitable for rectal administration. The rectal composition optionally further comprises at least one additional active agent. Also provided is a combination composition optionally further comprising a vasoconstrictor. Exemplary tapinarof rectal compositions are tapinarof, tapinarof-mesalamine, tapinarof- mesalamine-pramoxine and tapinarof-budesonide compositions.
-
公开(公告)号：WO2020194313A1
公开(公告)日：2020-10-01
申请号：PCT/IL2020/050369
申请日：2020-03-26
发明人： ARKIN, Moshe
摘要： The present invention, in some embodiments thereof, relates to treatment of hidradenitis suppurativa by topical or intralesional administration of a composition comprising tapinarof and optionally at least one additional active agent. The composition of the present invention is useful for the treatment, prevention or amelioration of hidradenitis suppurativa.
-
公开(公告)号：WO2020188575A1
公开(公告)日：2020-09-24
申请号：PCT/IL2020/050334
申请日：2020-03-19
发明人： ARKIN, Moshe
IPC分类号： A61P17/00 , A61K31/327 , A61K31/65 , A61K9/12 , A61K8/49 , A61K9/00 , A61K9/10 , A61K9/70 , A61P17/10 , A61K31/4164
摘要： Provided herein is a topical combination composition comprising a therapeutically effective amount of at least one acaricidal active agent, a therapeutically effective amount of at least one essentially non-acaricidal anti-inflammatory active agent and a carrier suitable for topical administration for the treatment of rosacea. Also provided are combination compositions optionally further comprising a vasoconstrictor.
-
公开(公告)号：WO2022107131A1
公开(公告)日：2022-05-27
申请号：PCT/IL2021/051362
申请日：2021-11-17
发明人： ARKIN, Moshe , TOLEDANO, Ofer , NEIMANN, Karine
摘要： This invention, in some embodiments thereof, relates to regimens, topical compositions comprising ruxolitinib, deuterated ruxolitinib or pharmaceutically acceptable salt thereof and uses thereof for the treatment of inflammatory skin conditions.
-
公开(公告)号：WO2022044005A1
公开(公告)日：2022-03-03
申请号：PCT/IL2021/051038
申请日：2021-08-24
摘要： The present disclosure, in some embodiments, relates to a low permeable topical composition comprising roflumilast, N -oxide of roflumilast or salts thereof, and to a method of treatment of a skin disorder by topical administration of said composition.
-
公开(公告)号：WO2021090322A1
公开(公告)日：2021-05-14
申请号：PCT/IL2020/051153
申请日：2020-11-05
发明人： ARKIN, Moshe , ZIGHELBOIM, Marcel , LEVY-HACHAM, Ofra , NOV, Ori
摘要： The present invention, in some embodiments, relates to a method of treatment, prevention or alleviation of Palmoplantar Keratoderma (PPK) in a patient in need thereof, comprising a debridement step followed by topical administration of a composition comprising at least one Epidermal Growth Factor Receptor (EGER) inhibitor.
-
公开(公告)号：WO2021084541A1
公开(公告)日：2021-05-06
申请号：PCT/IL2020/051131
申请日：2020-10-29
发明人： ARKIN, Moshe , ZIGHELBOIM, Marcel , NOV, Ori , NEIMANN, Karine
IPC分类号： A61K45/00 , A61P17/04 , A61K31/517 , A61K31/506
摘要： Disclosed are topical compositions and methods of treatment of hair loss by topical administration to a subject in need thereof of a composition comprising a therapeutically effective amount of at least one EGFR inhibitor and optionally at least one additional active agent. Also disclosed are methods of treatment of hair loss disorders by combining topical administration to a subject in need thereof of a composition comprising at least one EGFR inhibitor and optionally at least one additional active agent with oral administration of at least one additional active agent. Alternatively, the topical administration is combined with scalp cooling during therapy.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.012 秒)
